Management guided for 1) New launches and better MR productivity to lead growth in FY22E 2) launch derma products with addition of new MRs within next 2 quarters and 3) will continue to outperform in covered markets and IPM. We continue to prefer ERIS as one of our top picks in mid-cap space due to 1) pure domestic play with insignificant regulatory and currency risk, 2)...